ESTRO 2023 - Abstract Book

S1070

Digital Posters

ESTRO 2023

partial response (53%), and stable disease (40%). We have not reported severe toxicity in acute, but we have recorded 2 cases of late G3 toxicity in the form of dyspnea and pain. The table shows the cumulative doses of the two treatments on the OARs, converted in EQD2 and summed. The ratio alpha/beta of the spinal cord was considered equal to 2, of the other organs at risk 3 and PTV 10.

Conclusion The use of SABR on previously treated lesions by SABR is an option. The treatment is safe and the doses are acceptable. More studies with more patients can be necessary to predict and avoid severe toxicities.

PO-1336 Prognosticator of SBRT efficacy and toxicity in early-stage NSCLC patients

D. Walz 1,2 , P. Salome 1,2 , F. Sforazzini 1,2 , A. Kudak 3,4 , M. Dostal 5,4 , S. Regnery 6 , K. Schlamp 7 , C.P. Heußel 8 , F. Herth 9 , M. Thomas 10 , J. Hoerner-Rieber 11 , J. Debus 12 , M. Knoll 12 , A. Abdollahi 12 1 German Cancer Research Center (DKFZ), CCU Translational Radiation Oncology, Heidelberg, Germany; 2 Heidelberg University Hospital (UKHD), Faculty of Medicine (MFHD), Division of Molecular and Translational Radiation, German Cancer Consortium (DKTK) Core-Center Heidelberg, National Center for Tumor Diseases (NCT), Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany; 3 Heidelberg University Hospital (UKHD), Division of Molecular and Translational Radiation, German Cancer Consortium (DKTK) Core-Center Heidelberg, National Center for Tumor Diseases (NCT), Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany; 4 German Cancer Research Center (DKFZ), National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), CCU Radiation Therapy, Heidelberg, Germany; 5 Heidelberg University Hospital (UKHD), Division of Molecular and Translational Radiation, German Cancer Consortium (DKTK) Core-Center Heidelberg, National Center for Tumor Diseases (NCT), Heidelberg Ion-Beam Therapy Center (HIT) , Heidelberg, Germany; 6 Heidelberg University Hospital (UKHD) , Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; 7 Heidelberg University Hospital (UKHD), Translational lung research center and Dep. of Pneumology and Critical Care Medicine Thoraxklinik, National Center for Tumor Diseases (NCT), German Center for Lung Research (DZL), Heidelberg, Germany; 8 Heidelberg University Hospital (UKHD), Translational lung research center and Dep. of Pneumology and Critical Care Medicine Thoraxklinik, National Center for Tumor Diseases (NCT), Heidelberg, Germany; 9 Heidelberg University Hospital (UKHD), Translational lung research center and Dep. of Pneumology and Critical Care Medicine Thoraxklinik, National Center for Tumor Diseases (NCT) , Heidelberg, Germany; 10 Heidelberg University Hospital (UKHD), Translational lung research center and Dep. of Pneumology and Critical Care Medicine Thoraxklinik, National Center for Tumor Diseases (NCT), Dpt. Thoracic Oncology, Thoraxklinik, Heidelberg, Germany; 11 Heidelberg University Hospital (UKHD), Department of Radiation Oncology, CCU Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg Institute for Radiation Oncology (HIRO), National Center for Tumor Diseases (NCT), Heidelberg, Germany; 12 Heidelberg University Hospital (UKHD), Faculty of Medicine (MFHD), Division of Molecular and Translational Radiation, German Cancer Consortium (DKTK) Core Center Heidelberg, National Center for Tumor Diseases (NCT), Heidelberg Ion-Beam Therapy Center (HIT), CCU Translational Radiation Oncology, German Cancer Research Center (DKFZ), National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany

Purpose or Objective